An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

Medical clinics in the western Bay of Plenty area are experiencing a spike in people presenting with influenza and Covid-19 ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

Australia's vaccination rates against COVID and influenza are below ideal figures, but could a future innovation be able to ...

Solid phase III efficacy results for Moderna Inc.’s seasonal influenza vaccine, mRNA-1010, may lead the company to resubmit a ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

PRN02047 To: integrated care boards – chief executives GP practices community pharmacies primary care networks NHS trusts – chief executives local government chief executives health and justice ...

clearing a path forward for the product and the company's separate combination flu and Covid jab. Moderna in May voluntarily withdrew an application seeking approval of its combination shot targeting ...

Monitoring fungal spores in the outdoor air can predict surges in flu and COVID-19 infections, especially during the fall, ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...